Recombinant Mouse Egln3 Protein ，His

EGLN3, also known as Egl-9 family hypoxia-inducible factor 3, is a member of the EGLN (Egl-9 family of proteins) family that plays a crucial role in the cellular response to hypoxia. This protein functions as a prolyl hydroxylase, which regulates the stability and activity of hypoxia-inducible factors (HIFs) by hydroxylating specific proline residues. In normoxic conditions, EGLN3 mediates the degradation of HIFs, preventing the transcription of genes that facilitate adaptation to low oxygen levels. Conversely, under hypoxic conditions, EGLN3 activity decreases, allowing for the stabilization and accumulation of HIFs, which in turn activate a range of genes involved in angiogenesis, erythropoiesis, and metabolic adaptation. Research on recombinant EGLN3 protein has gained importance due to its potential implications in understanding various physiological and pathological processes, including cancer biology, where tumor cells often exploit hypoxic pathways for survival and growth. Moreover, the modulation of EGLN3 activity is being explored as a therapeutic strategy in diseases characterized by inadequate oxygen supply, such as ischemic conditions and certain genetic disorders. The study of recombinant EGLN3 not only enhances our understanding of its enzymatic mechanisms but also paves the way for the development of novel interventions targeting hypoxic responses in diverse diseases. Thus, the investigation of EGLN3 recombinant protein is pivotal for advancing our knowledge of hypoxia-related biology and for the potential development of innovative therapeutic strategies.